The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Immune fitness and reconstitution after CAR T-cell therapy in multiple myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses immune fitness and immune reconstitution in multiple myeloma following CAR T-cell therapy and T-cell engagers. She highlights the potential impact of T-cell phenotypes and clonal expansion on treatment response and toxicity, while noting the need to translate high-dimensional immune profiling into clinically actionable tests. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
